Related Experiment Video
Updated: Sep 23, 2025
RhoC GTPase Activation Assay
Published on: August 22, 2010
RHOA takes the RHOad less traveled to cancer
Antje Schaefer1, Channing J Der1
1University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Department of Pharmacology, Chapel Hill, NC 27599, USA.
Abstract:
RAS and RHO GTPases function as signaling nodes that regulate diverse cellular processes. Whereas RAS mutations were identified in human cancers nearly four decades ago, only recently have mutations in two RHO GTPases, RAC1 and RHOA, been identified in cancer. RAS mutations are found in a diverse spectrum of human cancer types. By contrast, RAC1 and RHOA mutations are associated with distinct and restricted cancer types. Despite a conservation of RAS and RAC1 residues that comprise mutational hotspots, RHOA mutations comprise highly divergent hotspots. Whereas RAS and RAC1 act as oncogenes, RHOA may act as both an oncogene and a tumor suppressor. Thus, while RAS and RHO each take different mutational paths, they arrive at the same biological destination as cancer drivers.
Insights
RAS and RHO GTPases are key regulators of cell processes. While RAS mutations are common in many cancers, RAC1 and RHOA mutations are specific to certain cancer types, impacting their roles as oncogenes or tumor suppressors.
Area of Science:
- Molecular biology
- Oncology
- Cell signaling
Background:
- RAS and RHO GTPases are crucial signaling proteins regulating cellular functions.
- RAS mutations have been recognized as cancer drivers for decades.
- Mutations in RHO GTPases RAC1 and RHOA are recently identified in cancer.
Purpose of the Study:
- To compare the mutational landscape and functional roles of RAS and RHO GTPases in cancer.
- To elucidate the distinct patterns of RAC1 and RHOA mutations in human cancers.
Main Methods:
- Bioinformatic analysis of cancer mutation databases.
- Comparative analysis of mutation hotspots.
- Functional characterization of GTPase mutations in oncogenesis.
Main Results:
- RAS mutations occur across a wide range of cancer types.
- RAC1 and RHOA mutations are restricted to specific cancer types.
- RAS and RAC1 share conserved mutational hotspots, acting as oncogenes.
- RHOA exhibits divergent mutational hotspots and can function as an oncogene or tumor suppressor.
Conclusions:
- Despite distinct mutational pathways, RAS and RHO GTPases are significant cancer drivers.
- RHOA's dual role as an oncogene and tumor suppressor highlights its complex involvement in cancer.
- Understanding these GTPase mutations provides insights into cancer development and potential therapeutic targets.
More Related Videos
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Related Concept Videos
01:24Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
02:38The Ras Gene
Ras is a...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:21Cell Polarization by Rho Proteins
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...